Argen X SE - ADR
NASDAQ:ARGX 3:59:59 PM EDT
| Market Cap (Intraday) | 14.23B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $289.20 |
| 50-Day MA | $312.67 |
| 200-Day MA | $305.27 |
Argen X SE - ADR Stock, NASDAQ:ARGX
Willemstraat 5, Breda, Noord-Brabant 4811 AH
Netherlands
Phone: +31.76.303.04.88
Number of Employees: 336
Description
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.